Deya Corzo, MD is best known for her successful leadership of first-in-class product development, worldwide launch and post-launch programs in the orphan diseases and oncology arenas.
Dr. Corzo led the medical team for the global development and launch of Myozyme®, the Genzyme multi-award winning enzyme replacement therapy for Pompe disease. Her commitment to the highest standards of patient ethics and for creating collaborative, responsive relationships within the complex global scientific, academic and regulatory communities resulted in a second BLA submission, and subsequent approval of Lumizyme®, another life-saving enzyme replacement therapy for Pompe disease. Dr. Corzo’s Medical Affairs experience includes US and global life-cycle management responsibilities for two highly successful oncology drugs: Velcade®, a first in class proteasome inhibitor developed by Millennium/Takeda for hematological cancers; and Abraxane®, an innovative formulation of paclitaxel commercialized by Celgene for solid cancers.
Dr. Corzo is double-board certified in Pediatrics and Clinical Genetics; she is an Instructor in Pediatrics at Harvard Medical School, and an active practicing physician at the Children’s Hospital Genetics Clinic in Boston.